110 related articles for article (PubMed ID: 8007520)
1. [Therapeutic potential of sparfloxacin for preventing mycobacterial infections].
Kawahara S; Tada A; Takeuchi M; Kamisaka K; Okada C; Mishima Y; Soda R; Takahashi K; Kibata M; Nagare H
Kekkaku; 1994 May; 69(5):351-6. PubMed ID: 8007520
[TBL] [Abstract][Full Text] [Related]
2. [Antimycobacterial activities of a new quinolone, sparfloxacin].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Oct; 66(10):643-9. PubMed ID: 1660089
[TBL] [Abstract][Full Text] [Related]
3. [In vitro antimycobacterial activity of a new quinolone, NM394].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Aug; 68(8):517-20. PubMed ID: 8397311
[TBL] [Abstract][Full Text] [Related]
4. [In vitro antimycobacterial activity of a new quinolone, T-3761].
Tomioka H; Sato K; Saito H
Kekkaku; 1995 Feb; 70(2):97-101. PubMed ID: 7699982
[TBL] [Abstract][Full Text] [Related]
5. [Antimycobacterial activity of a newly synthesized fluoroquinolone, Y-26611].
Tomioka H; Sato K; Saito H; Ikeda Y
Kekkaku; 1992 Jul; 67(7):515-20. PubMed ID: 1331603
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.
Saito H; Tomioka H; Sato K; Dekio S
Antimicrob Agents Chemother; 1994 Dec; 38(12):2877-82. PubMed ID: 7695276
[TBL] [Abstract][Full Text] [Related]
7. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.
Tomioka H; Saito H; Sato K
Antimicrob Agents Chemother; 1993 Jun; 37(6):1259-63. PubMed ID: 8392307
[TBL] [Abstract][Full Text] [Related]
8. [In vitro activities of newly developed quinolones, fleroxacin, lomefloxacin and sparfloxacin against Mycobacterium tuberculosis].
Kawahara S; Kamisaka K; Tada A; Nakada H; Mishima Y; Yoshimoto S; Matsuyama T; Kibata M; Nagare J
Kekkaku; 1991 Jun; 66(6):429-31. PubMed ID: 1942726
[TBL] [Abstract][Full Text] [Related]
9. [Antimicrobial activity of new quinolones against Mycobacterium avium and Mycobacterium intracellulare determined by the dilution methods using 7H11 agar and Ogawa egg media].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 May; 68(5):367-70. PubMed ID: 8331881
[TBL] [Abstract][Full Text] [Related]
10. [In vitro antimycobacterial activities of a new quinolone, balofloxacin].
Kawahara S; Tada A; Nagare H
Kekkaku; 2001 Jan; 76(1):29-31. PubMed ID: 11211780
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].
Kawahara S; Tada A; Nagare H
Kekkaku; 2001 Apr; 76(4):357-62. PubMed ID: 11398326
[TBL] [Abstract][Full Text] [Related]
12. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
[TBL] [Abstract][Full Text] [Related]
13. [Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media].
Yamane N; Chilima BZ; Tosaka M; Okazawa Y; Tanno K
Kekkaku; 1996 Aug; 71(8):453-8. PubMed ID: 8831190
[TBL] [Abstract][Full Text] [Related]
14. [Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections].
Kawahara S; Nagare H
Kekkaku; 1998 Feb; 73(2):77-82. PubMed ID: 9545700
[TBL] [Abstract][Full Text] [Related]
15. [In vitro antimicrobial activity of a new quinolone, levofloxacin, against atypical mycobacteria].
Oya S; Takemoto A; Hosaka K; Kudou Y; Arakawa M
Kekkaku; 1995 Nov; 70(11):615-9. PubMed ID: 8656585
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis.
Piersimoni C; Morbiducci V; Bornigia S; De Sio G; Scalise G
Am Rev Respir Dis; 1992 Dec; 146(6):1445-7. PubMed ID: 1333738
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of a newly developed broth microdilution test method to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for mycobacteria].
Yamane N; Nakasone I; Saitoh H; Kaneda M; Shimojima M; Yamashita K; Toyoda K; Okazawa Y
Rinsho Byori; 1998 Jul; 46(7):719-27. PubMed ID: 9721542
[TBL] [Abstract][Full Text] [Related]
18. [In vitro determination of the sensitivity of mycobacteria to fluoroquinolones].
Dailloux M; Petitpain N; Henry C; Weber M
Pathol Biol (Paris); 1989 May; 37(5):346-9. PubMed ID: 2780092
[TBL] [Abstract][Full Text] [Related]
19. [Sulfadimethoxine as a promising drug in the treatment of infections caused by Mycobacterium kansasii and Mycobacterium xenopi--differentiation between M. kansasii and M. marinum and between M. gordonae and M. scrofulaceum by the susceptibility testing to sulfadimethoxine].
Tsukamura M
Kekkaku; 1989 Apr; 64(4):313-7. PubMed ID: 2747117
[TBL] [Abstract][Full Text] [Related]
20. [Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi].
Gevaudan MJ; Bollet C; Mallet MN; de Lamballerie X; Sambuc R; de Micco P
Pathol Biol (Paris); 1992 May; 40(5):443-9. PubMed ID: 1323093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]